Evidence for Pleiotropic Signaling at the Mouse β3-Adrenoceptor Revealed by SR59230A [3-(2-Ethylphenoxy)-1-[(1,S)-1,2,3,4-tetrahydronapth-1-ylamino]-2 S-2-propanol Oxalate]
- 1 March 2005
- journal article
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 312 (3) , 1064-1074
- https://doi.org/10.1124/jpet.104.076901
Abstract
This study examines the action of the β3-adrenoceptor antagonist SR59230A [3-(2-ethylphenoxy)-1-[(1,S)-1,2,3,4-tetrahydronapth-1-ylamino]-2S-2-propanoloxalate] at cloned mouse β3-adrenoceptors expressed in Chinese hamster ovary cells (CHO-K1-β3) or endogenously expressed in 3T3-F442A adipocytes or ileum. SR59230A displayed partial agonist properties compared with the β3-adrenoceptor agonist CL316243 [(R,R)-5-[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]-amino]-propyl]1,3-benzodioxole-2,2-dicarboxylate] in CHO-K1-β3 with the intrinsic activity increasing with the level of receptor expression. Functional affinity values for SR59230A at each level of receptor expression were in agreement with pKI values determined by binding. In cytosensor microphysiometer studies, SR59230A was a full agonist for increases in extracellular acidification rates (ECARs) at all levels of receptor expression, and antagonist actions were measurable only in medium- or low-expressing cells. In 3T3-F442A adipocytes, SR59230A antagonized CL316243-mediated increases of cAMP and had no agonist actions. However, in the cytosensor micro-physiometer, SR59230A (acting via β3-adrenoceptors) was an agonist with an intrinsic activity greater than CL316243. In mouse ileum, SR59230A relaxed smooth muscle, although concentration-response curves were biphasic. Relaxant effects were produced by concentrations that did not affect cAMP levels. Differences in tissue responses to SR59230A were not caused by major differences in expression of Gαs. ECAR responses were not affected by pretreatment of cells with pertussis toxin, indicating that signaling did not involve Gi. Therefore, SR59230A displays agonist and antagonist actions at the mouse β3-adrenoceptor. Because SR59230A only antagonized accumulation of cAMP in 3T3-F442A adipocytes yet in the same cells was an agonist for ECAR, cAMP-independent signaling pathways must mediate part of the agonist actions in the microphysiometer.Keywords
This publication has 37 references indexed in Scilit:
- Evidence against β3 -adrenoceptors or low affinity state of β1 -adrenoceptors mediating relaxation in rat isolated aortaBritish Journal of Pharmacology, 2003
- β-Adrenergic Activation of p38 MAP Kinase in AdipocytesJournal of Biological Chemistry, 2001
- Direct Binding of Activated c-Src to the β3-Adrenergic Receptor Is Required for MAP Kinase ActivationPublished by Elsevier ,2000
- Qualitative and quantitative assessment of relative agonist efficacyBiochemical Pharmacology, 1999
- Influence of β-adrenoceptor agonists on the pulmonary circulation. Effects of a β3-adrenoceptor antagonist, SR 59230AEuropean Journal of Pharmacology, 1998
- Developmental expression and functional activity of β1- and β3-adrenoceptors in murine 3T3-F442A differentiating adipocytesEuropean Journal of Pharmacology, 1996
- Differential interaction of β1- and β3-adrenergic receptors with Gi in rat adipocytesCellular Signalling, 1994
- β3 and Atypical β‐AdrenoceptorsMedicinal Research Reviews, 1993
- Operational models of pharmacological agonismProceedings of the Royal Society of London. B. Biological Sciences, 1983
- Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reactionBiochemical Pharmacology, 1973